PDL BioPharma Operating Income 2010-2020 | PDLI
PDL BioPharma operating income from 2010 to 2020. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
PDL BioPharma Annual Operating Income
(Millions of US $) |
| 2020 |
$ |
| 2019 |
$-100 |
| 2018 |
$-51 |
| 2017 |
$194 |
| 2016 |
$129 |
| 2015 |
$550 |
| 2014 |
$546 |
| 2013 |
$427 |
| 2012 |
$355 |
| 2011 |
$344 |
| 2010 |
$211 |
| 2009 |
$297 |
PDL BioPharma Quarterly Operating Income
(Millions of US $) |
| 2020-12-31 |
|
| 2020-06-30 |
$-14 |
| 2020-03-31 |
$-32 |
| 2019-12-31 |
$-92 |
| 2019-09-30 |
$9 |
| 2019-06-30 |
$-9 |
| 2019-03-31 |
$-8 |
| 2018-12-31 |
$33 |
| 2018-09-30 |
$37 |
| 2018-06-30 |
$-125 |
| 2018-03-31 |
$4 |
| 2017-12-31 |
$30 |
| 2017-09-30 |
$33 |
| 2017-06-30 |
$113 |
| 2017-03-31 |
$19 |
| 2016-12-31 |
$-8 |
| 2016-09-30 |
$33 |
| 2016-06-30 |
$11 |
| 2016-03-31 |
$93 |
| 2015-12-31 |
$162 |
| 2015-09-30 |
$116 |
| 2015-06-30 |
$131 |
| 2015-03-31 |
$142 |
| 2014-12-31 |
$99 |
| 2014-09-30 |
$159 |
| 2014-06-30 |
$156 |
| 2014-03-31 |
$132 |
| 2013-12-31 |
$108 |
| 2013-09-30 |
$92 |
| 2013-06-30 |
$142 |
| 2013-03-31 |
$85 |
| 2012-12-31 |
$85 |
| 2012-09-30 |
$80 |
| 2012-06-30 |
$121 |
| 2012-03-31 |
$70 |
| 2011-12-31 |
$68 |
| 2011-09-30 |
$80 |
| 2011-06-30 |
$118 |
| 2011-03-31 |
$78 |
| 2010-12-31 |
$-28 |
| 2010-09-30 |
$75 |
| 2010-06-30 |
$112 |
| 2010-03-31 |
$53 |
| 2009-12-31 |
$53 |
| 2009-09-30 |
$66 |
| 2009-06-30 |
$120 |
| 2009-03-31 |
$58 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Biomedical and Genetics |
$0.000B |
$0.000B |
|
Protein Design Labs Inc. is a biopharmaceutical company focused on the research, development and commercialization of novel therapies for inflammation and autoimmune diseases, acute cardiac conditions and cancer. PDL markets several biopharmaceutical products in the United States through its hospital sales force and wholly-owned subsidiary, ESP Pharma, Inc. As a leader in the development of humanized antibodies, PDL has licensed its patents to numerous pharmaceutical and biotechnology companies, some of which are now paying royalties on net sales of licensed products.
|
